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A localized left breast ductal invasive triple-negative
breast carcinoma (TNBC) was diagnosed in a 44-year-
old woman. After surgery, she was treated with chemo-
therapy and radiation therapy in accordance with na-
tional guidelines. At the end of treatment, she had local
and metastatic relapse with multiple sub-diaphragmatic
lymph nodes.
With her written consent, imagery-guided biopsies of
a metastatic lymph node were performed, one sample
being used for genomic analyses and another for imme-
diate xenograft (Additional file 1: Supplementary
methods). Because of the early metastases after doce-
taxel and epirubicin-cyclophosphamide, she received cis-
platin but the disease progressed after 3 months.
Meanwhile, the transcriptomic analysis of the meta-
static sample enabled a molecular subclassification as
Basal-Like 2 with EGFR mRNA overexpression [1,2]. We
did not find any EGFR or K-RAS mutation. After suc-
cessful engraftment of the metastastic samples, we tested
eight different chemotherapies over 1 month on the
xenograft model. The combination of paclitaxel and
cetuximab was the most efficient (Figure 1A), so it was
offered to the patient. After 3 months of this second-line
treatment, the metabolic response was almost complete
(Figure 1B, C).
In compliance with French bioethics law (#2004-800,
06/08/2004), the patient had been informed of the re-
search use of the part of her biopsy samples remaining
after diagnosis had been established and did not oppose
it. The treatment combining paclitaxel and cetuximab
was discussed and approved in a multidisciplinary meet-
ing and then offered to the patient. Informed written* Correspondence: guilhem.bousquet@sls.aphp.fr; anne.janin728@gmail.com
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search Board Ethics Committee (in French, ‘Comité de
Protection des Personnes’) approved this study (CPP Ile-
de-France #13218). The University Institute Board Ethics
Committee for experimental animal studies approved
this study (#2012-15/728-0115).
The occurrence of metastases heavily affects prognosis
for women with TNBC, with a median survival of under
15 months [3]. In addition, when progression occurs
after first-line chemotherapy, there is no standard care.
Primary tumors are heterogeneous at the cellular and
molecular level [4], and metastases derive from aggres-
sive clones that have usually acquired resistance to first-
line treatments. These tumor cells, which may be a mi-
nority in the primary tumor, are precisely those on
which drug efficiency needs to be tested for individual-
ized treatments for patients with metastases.
Recently, a molecular subclassification of TNBC was
established, a new step toward innovative personalized
treatments for patients with TNBC [1,2]. However, mo-
lecular analyses still have limitations, since molecular
biomarkers are integrated into complex pathways and
can rarely be directly used in daily oncologic practice.
These limitations make it necessary to implement a dif-
ferent, complementary method. Individual xenografts
from metastatic samples of TNBC are an additional, in-
novative tool and are more physiological than genomic
analysis, as the tumor is in a mammalian environment
and can be followed up over time. In pancreatic cancer,
which shares poor prognosis and high metastatic poten-
tial with TNBC, individual xenografts have been pro-
posed in a pilot study for personalized treatments [5].
Individual xenografts could also be proposed as a per-
sonalized therapeutic resort for women with metastatic
TNBC.
Figure 1 Individual xenograft efficiently guided treatment of a patient with metastatic triple-negative breast carcinoma. (A) In
vivo effects of drugs or combination of drugs in the xenograft model obtained from metastatic triple-negative breast carcinoma. Mice
(n = 5 per group of treatment) were treated with drugs or combinations of drugs. Tumors were measured every week, from 4 weeks
before the treatment started to 4 weeks after treatment. Tumor volumes were calculated at each time-point. The greatest tumor growth
inhibition is observed with the combination of paclitaxel and cetuximab (purple circle). (B) Positron emission tomography (PET), maximum
intensity projection. The left panel shows baseline PET with intense fluoro-deoxyglucose (FDG) uptake in sub-diaphragmatic breast and
lymph node lesions (white arrows); the right panel shows PET after two cycles of combined paclitaxel and cetuximab. There is a marked
decrease (88%) of SUVmax (maximum standardized uptake value within the region of interest) in target lesions (white arrows) and thus a
partial metabolic response according to PERCIST (PET Response Criteria in Solid Tumors) criteria. (C) Fused PET/computed tomography.
The left panel shows an image at baseline with intense FDG uptake in a left breast lesion (SUVmax = 17.2, white arrow) and in a
subcarinar lymph node (SUVmax = 14.3, white arrowhead); after two treatment cycles (right panel), SUVmax of both target lesions
(white arrow, white arrowhead) is below background level.
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TNBC: Triple-negative breast carcinoma.
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